SVB Leerink initiated coverage on LAVA Therapeutics with a new price target

4/19/21 7:00:15 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

SVB Leerink initiated coverage of LAVA Therapeutics with a rating of Outperform and set a new price target of $26.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LVTX

Date	Price Target	Rating	Analyst
12/12/2024	$11.00 → $2.00	Outperform → Market Perform	Leerink Partners
12/11/2024		Mkt Outperform → Mkt Perform	JMP Securities
10/25/2022	$9.00	Buy	H.C. Wainwright
11/16/2021	$24.00 → $20.00	Outperform	SVB Leerink
8/17/2021	$26.00 → $24.00	Outperform	SVB Leerink